NBIX today
$169.40-$5.01 (-2.87%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bearish
1 hourBearish
15 minBearish
5 minLeaning Bearish
Daily trend turns up above $146.91
Key levels
Resistance$186.12
Resistance$169.53
Support$159.94
Support$151.77
Latest news & SEC filings
AnalystGuggenheim kept its Buy rating on Neurocrine Biosciences (NBIX) and raised its price target to $224 from $207.
AnalystMorgan Stanley kept its Equal-Weight rating on Neurocrine Biosciences (NBIX) and raised its price target to $185 from $183.
AnalystRBC Capital kept its Outperform rating on Neurocrine Biosciences (NBIX) and lowered its price target to $190 from $198.
AnalystCanaccord Genuity kept its Buy rating on Neurocrine Biosciences (NBIX) and raised its price target to $220 from $210.
AnalystPiper Sandler kept its Overweight rating on Neurocrine Biosciences (NBIX) and raised its price target to $215 from $210.
All NBIX news →About Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company focused on neuroscience. It develops and sells treatments for tardive dyskinesia, Huntington's disease chorea, classic congenital adrenal hyperplasia, and, with AbbVie, endometriosis and uterine fibroids. Its main products are INGREZZA and CRENESSITY, sold primarily in the U.S. through specialty pharmacies and distributors. The company also has clinical programs in psychiatry, neurology, and endocrinology.
Based on the company's 10-K filed Feb 11, 2026.
Nasdaq · Healthcare
NEUROCRINE BIOSCIENCES INC (NBIX)
What Is the Price Target for NBIX?
SEPT Low Target
$150.00
SEPT Mid Target
$213.50
SEPT High Target
$253.00
Analyst Consensus
$213.50
Is NBIX a Buy or Sell Right Now?
Thesis
- •Revenue growing 21.4% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NBIX.
Start Free Trial →Is NBIX Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$191.57
50
Moat Score
NARROW
6/9
Piotroski Score
8.1
Altman Z-Score
What Is Smart Money Doing with NBIX?
Insider Signal
SELLING
0 buys / 13 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| MORROW GEORGE J | director | Buy | 7,200 | $386K | Nov 3, 2026 |
| MORROW GEORGE J | director | Sale | 100 | $16K | Nov 3, 2026 |
| MORROW GEORGE J | director | Sale | 600 | $98K | Nov 3, 2026 |
| MORROW GEORGE J | director | Sale | 1,226 | $202K | Nov 3, 2026 |
| MORROW GEORGE J | director | Sale | 908 | $150K | Nov 3, 2026 |
| MORROW GEORGE J | director | Sale | 1,466 | $244K | Nov 3, 2026 |
| MORROW GEORGE J | director | Sale | 1,500 | $252K | Nov 3, 2026 |
| MORROW GEORGE J | director | Sale | 1,300 | $219K | Nov 3, 2026 |
| MORROW GEORGE J | director | Buy | 7,500 | $402K | Nov 2, 2026 |
| MORROW GEORGE J | director | Sale | 1,900 | $275K | Nov 2, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →NBIX Growth Story
Revenue YoY
21.4%
3yr Revenue CAGR
24.3%
EPS Growth YoY
41.95%
FCF Growth YoY
34.4%
Revenue Trend
STRONG
Dark Pool Trades for NBIX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for NBIX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:08:01 | $169.40 | 2,869 | $$486K | SELL |
| 21:00:39 | $169.40 | 2,337 | $$396K | SELL |
| 21:00:39 | $169.40 | 3,928 | $$665K | SELL |
| 21:00:39 | $169.40 | 4,880 | $$827K | SELL |
| 21:00:06 | $169.40 | 1,990 | $$337K | SELL |
5 dark pool trades shown · $$2.7M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for NBIX
PREVIEWSEPT Investing provides real-time options flow tracking for NBIX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $100 | Feb 19 | 99 | $$7543 | 1 | SWEEP |
| PUT | $110 | Feb 19 | 99 | $$108 | 1 | SWEEP |
| CALL | $90 | Mar 19 | 127 | $$8570 | 1 | SWEEP |
| PUT | $100 | Mar 19 | 127 | $$111 | 1 | SWEEP |
| PUT | $110 | Feb 19 | 99 | $$171 | 1 | SWEEP |
5 options trades shown · 40% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for NEUROCRINE BIOSCIENCES INC (NBIX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (5 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NBIX — frequently asked questions
What is NBIX stock price today?
NEUROCRINE BIOSCIENCES INC (NBIX) is at $169.40, down 2.87% (-$5.01) at the Nov 12, 2026 close.
Why is NBIX stock moving today?
Latest NBIX news — Nov 4, 2026: Guggenheim kept its Buy rating on Neurocrine Biosciences (NBIX) and raised its price target to $224 from $207. · Nov 3, 2026: Morgan Stanley kept its Equal-Weight rating on Neurocrine Biosciences (NBIX) and raised its price target to $185 from $183.
What is the NBIX price target?
The average analyst price target for NBIX is $213.50, ranging from $150 to $253, based on 16 analysts. Latest: Morgan Stanley maintains on Nov 3, 2026.
What do analysts rate NBIX?
Analyst ratings for NBIX: 0 Buy, 39 Hold, 0 Sell — consensus Hold.
Did NBIX beat earnings?
NBIX last reported on Nov 2, 2026: EPS $3.29 vs $1.91 expected — a beat of 72.3%.
What is NBIX's P/E ratio?
NBIX trades at a P/E of 24.4 vs a Healthcare average of 17.7.
Does NBIX pay a dividend?
NBIX does not currently pay a dividend.
What are NBIX support and resistance levels?
Support: $159.94, $151.77, $143.75. Resistance: $169.53, $186.12.
What are insiders doing with NBIX?
Insider activity: SELLING, 0 buys and 13 sells in the last 90 days.
What is the latest news on NBIX?
Nov 4, 2026: Guggenheim kept its Buy rating on Neurocrine Biosciences (NBIX) and raised its price target to $224 from $207. · Nov 3, 2026: Morgan Stanley kept its Equal-Weight rating on Neurocrine Biosciences (NBIX) and raised its price target to $185 from $183. · Nov 3, 2026: RBC Capital kept its Outperform rating on Neurocrine Biosciences (NBIX) and lowered its price target to $190 from $198.